This Director of a Counseling Center experienced two gay youth suicides in the previous year. This DVD offers clear guidelines for multifaceted training and …
http://www.bipolarblues.com is a social networking utility for individuals suffering from the mental illness known as bipolar disorder. We aim to Combat Stig…
Corto sobre counseling (consultoría psicológica) realizado por Holos Capital el instituto más prestigioso de Argentina.
New York, NY (PRWEB) December 04, 2013
The medication safety advocates at DrugNews.net are announcing a new resource center for parents of children who have taken the antipsychotic drug Risperdal. The site will contain the latest research and safety warnings as well as updated legal news from lawsuits alleging side effects*.
DrugNews is a free resource designed to share the latest safety alerts, recalls, studies and legal news with those taking popular prescription drugs. Patients can avoid potential dangers, see if others are experiencing similar side effects and decide if they need legal advice.
Risperdal is an atypical antipsychotic drug approved to treat schizophrenia, bipolar disorder and autism in adults. However, Johnson & Johnson recently paid $ 2.2 billion in fines and pled guilty to allegations of promoting it for unapproved uses, such as treating ADHD in children**.
The DrugNews Risperdal Center has added studies linking the drug to alleged gynecomastia, or abnormal breast growth that can be accompanied by milk production***. A recent study also found antipsychotic drugs like Abilify, Risperdal, Seroquel and Zyprexa may allegedly triple the risk of type-2 diabetes in children****.
Parents have already filed lawsuits alleging Risperdal caused abnormal breast growth in children, leading to settlements by Johnson & Johnson*.
Anyone affected by alleged abnormal breast growth or diabetes after taking Risperdal is urged to visit DrugNews.net or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugNews only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Risperdal and other antipsychotic drugs, or to speak with a lawyer.
*Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618
**Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
***Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
****Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
Let me know of any ‘well known’ famous people with any kind of disorders not in this video,such as learning disabilites,autism,mental health etc in the comme…
Bipolar symptoms: bipolar disorder symptoms and bipolar test http://www.mybipolartest.org/ Bipolar disorder, also referred to as bipolar affective disorder, …
Marriage Sermons from Bishop T.D Jakes.
Video Rating: 4 / 5
Is bipolar just mood swings? What does it feel like to have bipolar? What’s the difference between Bipolar I and Bipolar II? Who diagnoses it? How is it trea…
Video Rating: 5 / 5
Drs. Chris Schimmel and Ed Jacobs discuss group leadership skills based on their book Group Counseling: Strategies and Skills and Impact Therapy.
Fort Lauderdale, Fla. (PRWEB) November 26, 2013
Out with the old and in with the new. After more than five years of waiting for the final rule on the Mental Health Parity and Addiction Equity Act, the results are in, and its good news according to the Sylvia Brafman Mental Health Center.
Were pleased to see that the Parity Act has finally been put into effect, said Ben Brafman, the founder and CEO of the Sylvia Brafman Mental Health Center. The final ruling ensures that mental health and addiction must be treated on par with physical and surgical health services. In the past, that wasnt always the case.
Insurance companies are now required to provide equal benefits and coverage for addiction and mental health as they do for other medical coverage. This is known as parity, and according to experts it is a big achievement for mental health treatment. The law applies to everyone covered under health policies offered by their employers, group plans, and the health insurance marketplace. Medicare and Medicaid are not affected.
Prior to parity, clients with a mental health disorder or addiction were extremely restricted as far as access to treatment, said Brafman, a 20-year veteran of the behavioral health industry. Insurers used to be able to deny coverage based on mental illness, and in effect that translated to denying mental health treatment to those who need it most. They cant do that anymore.
Any limitations on coverage must now be disclosed by insurers, including the standards used to determine limitations. Intensive outpatient treatment and residential treatment are also protected by the parity act, meaning that clients arent obligated to pay for their own accommodation during treatment. This is a first-time addition to insurance coverage, and establishes fair treatment between mental and medical services.
Although the new ruling expands mental health treatment, it does not necessarily open the floodgates for everyone, explained behavioral health expert Brafman. The law doesnt require insurers to cover all levels of treatment. It only stipulates that if they provide a certain level of treatment for physical health, they must do the same for mental health.
This expansion of care appears to be a step in the right direction for cutting down the stigma associated with addiction and mental illness. The final rule will be implemented from July 2014, although we may not see its full effects until the beginning of the following year.
The Sylvia Brafman Mental Health Center is a full service mental health facility located in Fort Lauderdale, Fla. Dedicated to helping individuals who suffer from mental illness find a path to living better, The Sylvia Brafman Mental Health Center offers a mental health program and support for a wide variety of mood and thought disorders including: depression, anxiety disorders, anger management, eating disorders, post-traumatic stress disorder (PTSD), bipolar disorder, schizophrenia and schizoaffective disorder. For more information on mental health treatment please contact The Sylvia Brafman Mental Health Center at 1-888-205-2775 or online at http://www.mentalhealthcenter.org.
Related Bipolar Disorder Press Releases
Dallas, TX (PRWEB) December 02, 2013
The DrugNews.net prescription drug safety center is announcing the launch of a new resource for patients taking the antiepileptic drug Topamax. The site will contain studies on birth defect side effects, safety alerts for patients, as well as legal news for any birth defect claims.
DrugNews is a resource site for those taking popular prescription drugs. By sharing the latest medication recalls, safety alerts, research and litigation news, patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.
Topamax is an epileptic drug manufactured by Johnson & Johnson that is prescribed for epilepsy, seizures, Lennox-Gastaut syndrome, bipolar disorder, migraine headaches and weight gain.
Unfortunately, experts have warned the drug may increase the risk of birth defects. The resource center has added an FDA warning that infants born to women taking Topamax during pregnancy may have a higher risk of cleft lip and/or cleft palate*.
Also, DrugNews has added a study from the United Kingdom suggesting the rate of birth defects like cleft lip and cleft palate is 11 times that of normal for children exposed to Topamax during pregnancy**.
So far, more than 130 families have filed a Topamax lawsuit alleging birth defects from the drug in a special court. The formal case is known as In re Topamax Litigation, 110602131, Court of Common Pleas, Philadelphia County, Pennsylvania.
Now, DrugNews has learned that a jury awarded one family $ 4 million*** and another $ 11 million**** in recent months in the first two trials over Topamax birth defects.
Anyone with a child affected by birth defects after taking Topamax is urged to visit DrugNews.net or speak with a lawyer about their legal options. However, due to the specialized nature of drug injury cases, DrugNews only recommends lawyers who have already handled Topamax lawsuits.
Visit http://www.DrugNews.net today for more information on the research, side effects and litigation news related to Topamax and other drugs, or to speak with a lawyer.
*FDA 3/4/11; http://www.fda.gov/Drugs/DrugSafety/ucm245085.htm
**Neurology, March 2008; neurology.org/content/71/4/272
***10/30/13, April Czimmer, et al. v. Ortho-McNeil-Janssen Pharmaceutica, No. 1105-03459, Pa. Comm. Pls., Philadelphia Co.; lexisnexis.com/legalnewsroom/litigation/b/litigation-blog/archive/2013/10/31/4-million-awarded-in-1st-pa-trial-alleging-birth-defect-from-topamax-epilepsy-drug.aspx
****11/18/13, Gurley v. Ortho-McNeil-Janssen Pharmaceutical, 110502251, Court of Common Pleas, Philadelphia County, Pennsylvania; bloomberg.com/news/2013-11-18/j-j-s-janssen-loses-11-million-jury-verdict-over-topamax.html
Find More Bipolar Disorder Press Releases